• Beijing Luzhu Biotechnology posted a net loss of RMB 61.62 million, narrowing 20.6% from a year earlier.
• Loss per share improved to RMB 0.31, versus RMB 0.39 a year earlier.
• R&D expenses fell 39.7% to RMB 30.33 million, while finance costs climbed 73.8% to RMB 4.74 million.
• Other income rose 39.4% to RMB 6.76 million, on higher government grants and rental income.
• Core product LZ901’s China BLA remained under NMPA review, with commercialization expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Luzhu Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299728), on August 26, 2026, and is solely responsible for the information contained therein.